prikaz prve stranice dokumenta Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice
  Download
PDF 430.02 KB
master's thesis
Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice
2022. urn:nbn:hr:184:893357
Novosel, Matilda
University of Rijeka
Faculty of Medicine
Department of Nuclear Medicine

Cite this document

Novosel, M. (2022). Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice (Master's thesis). Rijeka: University of Rijeka, Faculty of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:893357

Novosel, Matilda. "Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice." Master's thesis, University of Rijeka, Faculty of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:184:893357

Novosel, Matilda. "Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice." Master's thesis, University of Rijeka, Faculty of Medicine, 2022. https://urn.nsk.hr/urn:nbn:hr:184:893357

Novosel, M. (2022). 'Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice', Master's thesis, University of Rijeka, Faculty of Medicine, accessed 13 May 2024, https://urn.nsk.hr/urn:nbn:hr:184:893357

Novosel M. Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice [Master's thesis]. Rijeka: University of Rijeka, Faculty of Medicine; 2022 [cited 2024 May 13] Available at: https://urn.nsk.hr/urn:nbn:hr:184:893357

M. Novosel, "Liječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice", Master's thesis, University of Rijeka, Faculty of Medicine, Rijeka, 2022. Available at: https://urn.nsk.hr/urn:nbn:hr:184:893357

Please login to the repository to save this object to your list.
Metadata
TitleLiječenje diferenciranih karcinoma štitne žlijezde: uloga 131I i nove smjernice
Title (english)Treatment of differentiated thyroid cancer: the role of 131I and new guidelines
AuthorMatilda Novosel
MentorTatjana Bogović Crnčić (mentor)
Committee memberManuela Avirović (predsjednik povjerenstva)
Committee memberSvjetlana Grbac-Ivanković (član povjerenstva)
Committee memberFranjo Lovasić (član povjerenstva)
GranterUniversity of Rijeka
Faculty of Medicine
(Department of Nuclear Medicine)
Rijeka
Defense date and country2022, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Nuclear Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract
Karcinomi štitne žlijezde u stalnom su porastu. Papilarni i folikularni su najčešća varijanta i sa karcinomom Hurthleovih stanica nazivaju se diferencirani karcinomi štitne žlijezde te imaju bolju prognozu u odnosu na medularni i anaplastični. Ovisno o proširenosti i tipu karcinoma, postoji šest različitih metoda liječenja: operativno liječenje, terapija jodom-131, supresivna terapija levotiroksinom, radioterapija vanjskim snopom, ciljana terapija i kemoterapija. Temeljno liječenje diferenciranih karcinoma čine operativna terapija i potom primjena 131I. Primarni karcinom može se ukloniti lobektomijom ili totalnom tireoidektomijom. Totalna tireoidektomija češće se koristi zbog velike učestalosti multicentričnosti tumora i zahvaćenosti oba režnja žlijezde te je pokazala manji rizik od recidiva tumora većih od 1 cm. U liječenju metastatskog i rekurentnog karcinoma operacija je korisna kod resekcije ograničenih simptomatskih metastaza ili regionalnih limfnih čvorova, posebice kada je tumor refrakteran na 131I. Radiojodna terapija primjenjuje se nakon totalne tireoidektomije kako bi uništila sve preostale stanice zdravog i tumorskog tkiva štitnjače, bilo malignog ili suspektnog, te recidiva bolesti. Radioterapija vanjskim snopom i kemoterapija koriste se najviše u pacijenata čiji je karcinom neresektabilan, metastazirao ili čije stanje zahtijeva palijativnu terapiju zbog uznapredovale bolesti. Kemoterapija uglavnom ne daje zadovoljavajuće rezultate. Ciljana terapija je noviji modalitet liječenja koji daje odlične rezultate i sve se više koristi u slučaju proširene bolesti, recidiva ili metastaza koji su refrakterni na 131I. Prva linija sistemske ciljane terapije su inhibitori tirozin kinaze, čija primjena ima poseban značaj u liječenju karcinoma štitne žlijezde refrakternih na jod-131.
Abstract (english)
Thyroid cancers are on the rise. Papillary and follicular are the most common variants and with Hurthle cell cancer are called differentiated thyroid cancers. They have good prognosis compared to medullary and anaplastic. Depending on the extent and type of cancer, there are six different treatment methods: surgery, iodine-131 therapy, levothyroxine suppressive therapy, external beam radiotherapy, targeted therapy, and chemotherapy. The basic treatment consists of surgical therapy and the use of 131I. Primary cancer can be removed by lobectomy or total thyroidectomy. Total thyroidectomy is more commonly used due to the high frequency of multicentric tumours of the gland and has shown lower risk of tumour recurrence greater than 1 cm. In the treatment of metastatic and recurrent cancer, surgery is useful in resection of limited symptomatic metastases or regional lymph nodes, especially when the tumour is refractory to 131I. Radioiodine therapy is applied after total thyroidectomy to destroy all remnant cells and malignant thyroid tissue or recurrence of the disease. External beam radiotherapy and chemotherapy are mostly used in patients whose cancer is unresectable, metastatic, or whose condition requires palliative therapy due to advanced disease. Chemotherapy generally does not give satisfactory results. Targeted therapy is a newer treatment modality that gives excellent results and is increasingly used in case of extended disease, recurrence or metastasis that is refractory to 131I. The first line of systemic targeted therapy are tyrosine kinase inhibitors, the use of which is of particular importance in the treatment of thyroid cancers refractory to 131I.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:184:893357
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) icon
Created on2022-07-03 20:05:40